A must-attend event for any organisation seeking to bring their medicines, devices and diagnostics to UK patients.
Our conference has been designed around three core market access areas, each with a specific mission to bring you the latest insights and information for accelerating patient access.
Looking for the Patient Access ‘2020’ Conference?
With continued uncertainty for venues, live events and conferences due to COVID-19, we have decided to postpose the 2020 Patient Access conference to 2021. We are currently working with all the speakers to bring you the full programme as published below on Wednesday 22nd September 2021. Please register now and we will keep you updated.
Can’t wait until next year?
Join us for a series of FREE Patient Access Webinars and Virtual Panel Sessions. Taking place throughout September 2020, our conference speakers and expert panellists will answer your questions and unpack key topics around the Patient Access agenda. To register for these sessions, click here.
Developments in
strategy and HTA
The importance of patient engagement throughout the HTA process
Using patient registries in HTAs
Appraisal process of medical devices compared with drugs
Health economic modelling of digital apps
Access to Orphan Medicines: Developing policies for the future
Innovation tools
Approaches to utilising Real World Evidence (RWE)
Using analytics and big data to gain competitive advantage in Market Access
Collaborative working and horizon scanning
Harnessing digital systems and technology to find new levels of patient value
Pricing and policy
VPAS – what you need to know
Updates on The Commercial Framework
Advanced Therapy Medicinal Products – Responding to new high cost/high value drugs
The NHS Long Term Plan and what this actually means for pharma companies
Who should attend?
This conference should be attended by representatives from UK, European and global pharmaceutical, biotech, life science and MedTech industries, as well as patient organisations and patient groups.
The job functions that will benefit most include:
Heads of Market Access
Country Managers
Health Economists
Commercial Directors
Marketing Directors
Managing Directors
Chief Executives
Medical Directors
Policy Officers/Executives
Policy Advisors
Speakers
Lindsay Weaver
CEO, Metabolic Support UK
The importance of patient engagement throughout the HTA process
David Gillen
Vice President international Medical Affairs, Vertex
Using patient registries in HTAs
Melinda Goodall
Associate Director, NICE
Andi Orlowski
Head of Business Intelligence, Imperial College Healthcare Partners
Approaches to utilising Real World Evidence (RWE)
David Watson
Director Pricing And Reimbursement, Association of the British Pharmaceutical Industry (ABPI)
The Voluntary Scheme; what you need to know
Darren Spevick
Managing Partner, Eventum Partners and Chair of the EMIG Digital Health Special Interest Group
Harnessing digital systems and technology to find new levels of patient value
Carla Deakin
Programme Director, Commercial & Managed Access, NICE
Sarah Walker
Senior Consultant Policy and Public Affairs, MAP BioPharma
Kate Learoyd
Campaign Manager, NSPKU – National Society for Phenylketonuria
Christian Hill
CEO, MAP BioPharma
Exhibitors
We are an independent horizon scanning centre based at Newcastle University in the UK. We use advanced horizon scanning techniques to detect new health innovations and track them; from patent-to-patient.
NICE provide UK national guidance for the NHS through their NICE technology appraisal (TA) and highly specialised technology (HST) process. NIHRIO is industry’s gateway to NICE, notifying NICE about new or repurposed drugs 3 years before UK license. This early notification allows NICE to provide new technology guidance as close to the license date as possible, ensuring efficient UK market access.
O4 Research is a UK/Ireland based provider of innovative, sector leading clinical trial services and ‘On & Off’ site management solutions. For over a decade we have successfully delivered full and functional services for Top 20 Pharma, biotech and medical device clients across Clinical Phases II-IV and RWE studies. We understand the value of RWE and its role in the development of new healthcare interventions. Our scientific expertise, combined with advances in data acquisition, mean we are ideally placed to help you deliver a bespoke solution for timely and compelling evidence generation. We take the complex and make it simple.
EUCOPE is Europe’s trade body for small to medium-sized innovative companies working in the field of pharmaceuticals and medical technologies.
Based in Brussels, EUCOPE gives voice to more than 900 research-oriented innovative companies and associations active in research, development of pharmaceuticals, biotechnologies and medical devices. Many of our members are developing therapeutic solutions for persons living with a rare disease, who had little to no treatment available just a few years ago.
Agenda
Session One
08:30 – Morning coffee & registration
09:00 – Welcome to Patient Access 2020. Introductions and scene setting – Christian Hill, CEO MAP BioPharma
Developments in strategy and HTA
09:15 – The importance of patient engagement throughout the HTA process – Lindsay Weaver, CEO, Metabolic Support UK
09:45 – Using patient registries in HTAs – David Gillen, Vice President international Medical Affairs, Vertex
10:15 – Appraisal process of medical devices compared with drugs – Melinda Goodall, Associate Director, NICE
Break
10:45 – Refreshments & Networking; Guided tours of MAP Online resources and free consultation clinics; Meet our exhibitors: NIHR Innovation Observatory (NIHRIO); O4 Research; EUCOPE
Session Two
11:15 – Access to Orphan Medicines: Developing policies for the future – Sarah Walker, Senior Consultant Policy and Public Affairs, MAP BioPharma
11:45 – Panel Discussion: Led by MAP’s Policy and Public Affairs team, this interactive session will bring together experts to consider challenges with and solutions for the appraisal of medicines for rare diseases.
Panellists will reflect on the potential for the NICE methods review, proposed Innovative Medicines Fund and other policy levers to improve access to orphan medicines arrangements. Our panel includes:
Kate Learoyd, Campaign Manager, NSPKU – National Society for Phenylketonuria
Lindsay Weaver, CEO, Metabolic Support UK
Member of Parliament – tbc
Break
12:30 – Lunch & Networking; Guided tours of MAP Online resources and free consultation clinics; Meet our exhibitors: NIHR Innovation Observatory (NIHRIO); O4 Research; EUCOPE
Session Three - Innovation tools
13:30 – Approaches to utilising Real World Evidence (RWE) – Andi Orlowski, Head of Business Intelligence, Imperial College Healthcare Partners
14:00 – Collaborative working and Horizon Scanning – The NHS Long Term Plan and what this actually means for pharma companies
Melinda Goodall, Associate Director, NICE
14:30 – Harnessing digital systems and technology to find new levels of patient value – Darren Spevick, Managing Partner, Eventum Partners and Chair of the EMIG Digital Health Special Interest Group.
Break
15:00 – Refreshments & Networking; Guided tours of MAP Online resources and free consultation clinics; Meet our exhibitors: NIHR Innovation Observatory (NIHRIO); O4 Research; EUCOPE
Session Four - Pricing and policy
15:30 – VPAS – what you need to know – David Watson, Director Pricing And Reimbursement, Association of the British Pharmaceutical Industry (ABPI)
16:00 – Commercial and Managed Access in England – Carla Deakin, Programme Director, Commercial & Managed Access, NICE
16:30 – Advanced Therapy Medicinal Products – Responding to new high cost/high value drugs
Outputs from ‘meet the expert’ sessions across Europe in 2020 – Christian Hill, Chief Executive Officer, MAP
17:00 – Conference Close – Networking Drinks Reception
Book now
Copyright © 2020. MAP BioPharma Limited. All rights reserved.
MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
United Kingdom
+44 (0) 1480 832360
MAP BioPharma Limited is a registered company in England and Wales. Company Registration Number 08209281
VAT Group Registration Number GB 292 8576 52